Opportunity Information: Apply for RFA HL 23 002
The ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (RFA-HL-23-002) is an NIH cooperative agreement (U01) funding opportunity aimed at establishing a central Coordinating Center to run and support a multi-site research effort known as the Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping Consortium (APS Consortium). The overall purpose is to improve understanding of why patients with these critical illness syndromes can look similar clinically yet have very different underlying biology, disease trajectories, and recovery patterns. By focusing on heterogeneity and shared or distinct mechanisms across ARDS, pneumonia, and sepsis, the consortium is designed to enable more precise classification (phenotyping) of patients and, ultimately, to inform future targeted therapies and better approaches to care.
The scientific work supported by the consortium is described as a prospective, longitudinal observational study, meaning participants are followed forward in time and data are collected without assigning experimental interventions. The study will enroll 5,000 hospitalized adults diagnosed with one or more of the following: ARDS, pneumonia, and/or sepsis. A key feature is the use of common, standardized data elements and harmonized biospecimen collection across all participating sites so that results can be compared and pooled reliably. In addition to in-hospital information, the design expects that about half of the participants who are discharged will complete follow-up assessments at 3, 6, and 12 months. These follow-ups are intended to capture long-term outcomes and recovery, including how biological signals and physiological impairments resolve or persist after acute illness, which is especially important given the lasting disabilities many survivors experience.
The Coordinating Center is the operational backbone of this effort. While the announcement emphasizes the overall consortium goals more than a task-by-task scope in the provided text, the intent of a Coordinating Center in a large NIH consortium is typically to provide centralized leadership for study coordination across multiple clinical sites. That usually includes managing or supporting protocol implementation and consistency, overseeing common data and biospecimen standards, coordinating communication and governance across sites, ensuring high-quality and timely data capture (including imaging data), and facilitating the logistics of longitudinal follow-up. Because this is a cooperative agreement, the NIH is expected to have substantial programmatic involvement, with the Coordinating Center working collaboratively with NIH staff and participating sites rather than operating fully independently.
A major deliverable highlighted in the opportunity is the creation of a broadly usable community resource. Throughout the funding period, the consortium will make collected data, including imaging data, and biospecimens available to the wider research community as rapidly and simply as possible. This positions the project not only as a single study, but also as an infrastructure and repository effort that can accelerate additional research beyond the original consortium investigators. In practice, this kind of resource-forward model often implies strong expectations for data stewardship, documentation, standardization, and clear access processes so that external researchers can reuse the materials effectively and responsibly.
Eligibility is broad and includes many types of domestic U.S. organizations and governmental entities, such as state, county, and city governments; public and private institutions of higher education; federally recognized tribal governments; tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and other eligible entities. The announcement explicitly notes additional eligible applicant categories that NIH often calls out for emphasis, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
At the same time, the FOA draws clear boundaries around non-U.S. applicants. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as defined by the NIH Grants Policy Statement, are allowed. This distinction generally means the applicant organization must be U.S.-based, but it may be permissible to include certain well-justified activities conducted outside the U.S. as part of the project if they meet NIH policy requirements and are appropriately described and approved.
Administratively, the opportunity is listed under NIH with a discretionary funding category and a health activity focus, and it references CFDA numbers 93.837, 93.838, 93.839, and 93.859. The original closing date shown is June 17, 2022, and the FOA creation date is January 21, 2022. The award ceiling and expected number of awards are not specified in the provided source text. The title also states "Clinical Trial Not Allowed," reinforcing that the proposed work for this Coordinating Center should not include an NIH-defined clinical trial, aligning with the observational nature of the consortium study.
Overall, this FOA is about building and operating the central hub for a large, standardized, multi-site observational cohort of critically ill adults with ARDS, pneumonia, and sepsis, with a strong emphasis on long-term follow-up and on producing a high-value, shareable dataset and biospecimen resource for the broader scientific community.Apply for RFA HL 23 002
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837, 93.838, 93.839, 93.859.
- This funding opportunity was created on 2022-01-21.
- Applicants must submit their applications by 2022-06-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center opportunity (RFA-HL-23-002)?
This NIH funding opportunity supports a cooperative agreement (U01) to establish a central Coordinating Center for the Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping Consortium (APS Consortium). The Coordinating Center is intended to serve as the operational hub for a multi-site research effort focused on phenotyping and understanding heterogeneity across these critical illness syndromes.
What is the main goal of the APS Consortium described in this opportunity?
The consortium aims to improve understanding of why patients with ARDS, pneumonia, and sepsis can appear clinically similar yet differ substantially in underlying biology, disease trajectories, and recovery patterns. The work is designed to support more precise classification (phenotyping) of patients and to inform future targeted therapies and improved care approaches.
What type of study is the consortium conducting?
The scientific work is described as a prospective, longitudinal observational study. Participants are followed forward in time, and data are collected without assigning experimental interventions.
How many participants are expected to be enrolled, and who are they?
The study plans to enroll 5,000 hospitalized adults diagnosed with one or more of the following: ARDS, pneumonia, and/or sepsis.
Are participants followed after they leave the hospital?
Yes. The design expects that about half of participants who are discharged will complete follow-up assessments at 3, 6, and 12 months to capture longer-term outcomes and recovery.
Why does the study include follow-up at 3, 6, and 12 months?
The follow-ups are intended to measure long-term outcomes and recovery, including whether biological signals and physiological impairments resolve or persist after acute illness. This reflects the reality that many survivors experience lasting disabilities.
What does "phenotyping" mean in the context of this consortium?
In this context, phenotyping refers to more precise classification of patients based on shared or distinct biological mechanisms, trajectories, and recovery patterns, rather than relying only on clinical appearance.
What is the role of the Coordinating Center in this NIH consortium?
The Coordinating Center is described as the operational backbone of the consortium. Its role is to run and support the multi-site effort and provide centralized coordination to keep activities aligned across participating sites.
What kinds of responsibilities are typically associated with a Coordinating Center for a large NIH consortium?
While the provided text emphasizes overall consortium goals more than a task-by-task list, it notes that a Coordinating Center in a large NIH consortium is typically responsible for centralized leadership for study coordination across multiple clinical sites. This often includes supporting consistent protocol implementation, overseeing common data elements and harmonized biospecimen standards, coordinating communication and governance across sites, promoting high-quality and timely data capture (including imaging data), and facilitating logistics for longitudinal follow-up.
Is this award a standard research grant or something more collaborative?
It is a cooperative agreement (U01). That structure means NIH is expected to have substantial programmatic involvement, and the Coordinating Center is expected to work collaboratively with NIH staff and participating sites rather than operating fully independently.
Does this opportunity allow clinical trials?
No. The title states "Clinical Trial Not Allowed," which aligns with the observational design described for the consortium study.
What is meant by "common, standardized data elements" and "harmonized biospecimen collection" across sites?
The consortium is designed to use shared, standardized data elements and consistent biospecimen collection approaches at all participating sites so that results can be compared and pooled reliably.
Will imaging data be included in what the consortium collects?
Yes. The opportunity specifically mentions that collected data include imaging data, and it highlights expectations around high-quality and timely data capture, including imaging data.
What is a major deliverable expected from this consortium?
A major deliverable is the creation of a broadly usable community resource. Throughout the funding period, the consortium will make collected data (including imaging data) and biospecimens available to the wider research community as rapidly and simply as possible.
Who is expected to benefit from the data and biospecimen resource?
The wider research community is explicitly identified as a beneficiary, because the consortium intends to make data and biospecimens available beyond the original consortium investigators.
What does it mean that the project is "resource-forward"?
It means the consortium is positioned not only as a single study, but also as an infrastructure and repository effort intended to accelerate additional research. The description implies strong expectations for data stewardship, documentation, standardization, and clear access processes so external researchers can reuse materials effectively and responsibly.
Which organizations are eligible to apply?
Eligibility is broad and includes many types of domestic U.S. organizations and governmental entities. Examples listed include state, county, and city governments; public and private institutions of higher education; federally recognized tribal governments; tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other eligible entities.
Are specific institution types explicitly encouraged or highlighted as eligible?
Yes. The opportunity explicitly notes additional eligible applicant categories often called out by NIH, including HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and AANAPISIs. It also mentions faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
Can non-U.S. organizations apply?
No. Non-domestic (non-U.S.) entities are not eligible to apply.
Can a U.S. organization apply if it has a non-U.S. component?
Non-domestic components of U.S. organizations are not eligible to apply. However, foreign components (as defined by the NIH Grants Policy Statement) are allowed, which generally means the applicant must be U.S.-based, but certain justified activities conducted outside the U.S. may be permissible if they meet NIH policy requirements and are appropriately described and approved.
Which CFDA numbers are associated with this opportunity?
The opportunity references CFDA numbers 93.837, 93.838, 93.839, and 93.859.
What are the key dates shown for this funding opportunity?
The FOA creation date shown is January 21, 2022. The original closing date shown is June 17, 2022.
Is the award ceiling or the expected number of awards provided?
No. The award ceiling and expected number of awards are not specified in the provided information.
Which NIH mechanisms and administrative descriptors are mentioned?
The award mechanism is a U01 cooperative agreement. The opportunity is listed under NIH with a discretionary funding category and a health activity focus (as described in the provided information).
What syndromes are in scope for this consortium?
The consortium focuses on ARDS, pneumonia, and sepsis, including understanding shared and distinct mechanisms across these syndromes.
Why is standardization across multiple sites emphasized?
Because the consortium is multi-site and intended to generate results that can be compared and pooled reliably. Standardized data elements and harmonized biospecimen collection are core design features described in the opportunity.
What makes this Coordinating Center central to the consortium's success?
The Coordinating Center is positioned as the operational backbone for running and supporting the multi-site effort, enabling consistent implementation, communication, high-quality data collection, and the logistics needed for longitudinal follow-up and community-facing data/biospecimen sharing.
Browse more opportunities from the same category: Health
Next opportunity: Bureau of Land Management Colorado Cultural and Paleontological Resources Management
Previous opportunity: Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) (R01 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 23 002
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 23 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial Not Allowed) Apply for RFA HL 23 001 Funding Number: RFA HL 23 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed) Apply for RFA HL 23 011 Funding Number: RFA HL 23 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) Apply for RFA HL 23 010 Funding Number: RFA HL 23 010 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| NIMH Instrumentation Program (S10 Clinical Trial Not Allowed) Apply for RFA MH 22 155 Funding Number: RFA MH 22 155 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed) Apply for RFA HL 23 012 Funding Number: RFA HL 23 012 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Optional) Apply for PAR 22 113 Funding Number: PAR 22 113 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required) Apply for PAR 22 112 Funding Number: PAR 22 112 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| NHGRI Short Courses for Genomics-Related Research Education (R25 Clinical Trial Not Allowed) Apply for PAR 22 095 Funding Number: PAR 22 095 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| Strategic Project for Epidemic Control of Key Populations Apply for RFI 674 21 KEYPOPBOTSWANA Funding Number: RFI 674 21 KEYPOPBOTSWANA Agency: South Africa USAID-Pretoria Category: Health Funding Amount: $15,000,000 |
| NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U24 Clinical Trial Not Allowed) Apply for PAR 22 110 Funding Number: PAR 22 110 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) Apply for PAR 22 082 Funding Number: PAR 22 082 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dental Specialty and PhD Program (K12 Clinical Trial Not Allowed) Apply for RFA DE 23 001 Funding Number: RFA DE 23 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Mentored Career Development Award to Promote Diversity (K01 Clinical Trial Required) Apply for PAR 22 051 Funding Number: PAR 22 051 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed) Apply for PAR 22 050 Funding Number: PAR 22 050 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Mentored Career Development Award to Promote Diversity (K01 Independent Basic Experimental Studies with Humans Required) Apply for PAR 22 052 Funding Number: PAR 22 052 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD National Human Ear Resource Network (U24 Clinical Trial Not Allowed) Apply for RFA DC 23 002 Funding Number: RFA DC 23 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NEI - DOD Vision Research Collaborative (R01 Clinical Trial Optional) Apply for PAR 22 117 Funding Number: PAR 22 117 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data Management and Coordinating Center (DMCC) for the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC) (U24 Basic Experimental Studies with Humans Required) Apply for RFA NS 22 020 Funding Number: RFA NS 22 020 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54, Basic Experimental Studies Involving Humans Allowed) Apply for RFA NS 22 019 Funding Number: RFA NS 22 019 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| In utero Treatments of Congenital Dental and Craniofacial Disorders Using Precision Medicine Approaches (R21 Clinical Trial Not Allowed) Apply for RFA DE 23 005 Funding Number: RFA DE 23 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 23 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.